Document is current
Any future updates will be listed below
-
Authors
Dagan, Noa https://orcid.org/0000-0001-8811-7825
Elnekave, Eldad https://orcid.org/0000-0002-3197-7338
Barda, Noam https://orcid.org/0000-0002-3400-235X
Bregman-Amitai, Orna https://orcid.org/0000-0001-5534-5311
Bar, Amir
Orlovsky, Mila
Bachmat, Eitan https://orcid.org/0000-0001-7153-100X
Balicer, Ran D.
-
Funding
Funding for this research was provided by:
Israel Innovation Authority
- License Information
-
More Information
Article History
Received: 22 September 2019
Accepted: 26 November 2019
First Online: 13 January 2020
Competing interests
: E.B. has no interests to disclose. N.D., N.B. and R.D.B. report having received grants from the Israel Innovation Authority during the conduct of this study. The parent company of Clalit Research Institute (N.D., N.B. and R.D.B.) owns a minority share in Zebra Medical Vision. E.E., O.B.A., A.B. and M.O. report personal fees from Zebra Medical Vision during the conduct of this study. In addition, E.E. and O.B.A. have a patent for emulating DXA scores based on CT images (WO2016013005A3) and a patent to predict osteoporotic fracture risk (WO2016013004A1).
